RxDoctor Payments Data

Lily Tumbaga-Notario, MD

Internal Medicine · Lodi, CANPI 1710910336

Payments from drug & device makers

$1,943in general payments, 2019–2025

Across 121 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$295
  • Boehringer Ingelheim$291
  • Novartis$190
  • Johnson & Johnson$178
  • Kowa Pharmaceuticals America, Inc.$148
  • Novo Nordisk$107
  • plus $734 from 17 others

What the payments were for

  • Food & beverage$1,89898%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,943 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$252,397
Medicare patients
548
Services billed
3,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban114$94,149
TrulicityDulaglutide29$51,008
OzempicSemaglutide38$40,289
JardianceEmpagliflozin42$36,356
XareltoRivaroxaban30$33,929
MyrbetriqMirabegron32$31,996
LinzessLinaclotide37$31,648
JanuviaSitagliptin Phosphate25$28,445
FarxigaDapagliflozin Propanediol13$14,412
Tresiba Flextouch U-100Insulin Degludec19$13,777
MultaqDronedarone Hcl12$9,918
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$9,605
Rosuvastatin Calcium282$6,650
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen207$5,853
Icosapent Ethyl18$5,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$70$94,149114 claims
Lilly USA, LLCTrulicity$27$51,00829 claims
Novo NordiskOzempic$107$40,28938 claims
Boehringer IngelheimJardiance$291$36,35642 claims
AbbVieLinzess, Synthroid$53$34,93576 claims
Johnson & JohnsonXarelto$178$33,92930 claims
Astellas Pharma US IncMyrbetriq$70$31,99632 claims
MerckJanuvia$90$28,44525 claims
AstraZenecaFarxiga, Brilinta$295$19,50525 claims
GSKAnoro Ellipta, Breo Ellipta$26$13,75228 claims
Sanofi-aventis U.S. LLCMultaq, Lantus$15$12,02525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Lodi

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →